The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: Implications for cancer therapy

Biochemical Pharmacology

Volumn 76, Issue 2, 2008, Pages 188-197

  Bronckaers, Annelies ^a   Balzarini, Jan ^a   Liekens, Sandra ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Capecitabine; Cytostatic activity; Mycoplasma; Nucleoside analogues; Thymidine phosphorylase

Indexed keywords

5 CHLORO 6 [1 (2 IMINOPYRROLIDINYL)METHYL]URACIL; 5 TRIFLUOROTHYMIDINE; BROXURIDINE; CAPECITABINE; CLOXURIDINE; DEOXYURIDINE DERIVATIVE; DOXIFLURIDINE; FLOXURIDINE; FLUOROURACIL; IDOXURIDINE; NUCLEIC ACID; PYRIMIDINE NUCLEOSIDE; THYMIDINE PHOSPHORYLASE;

ARTICLE; BACTERIAL INFECTION; BREAST CANCER; CANCER THERAPY; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOSTASIS; DRUG DISTRIBUTION; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC CODE; HUMAN; HUMAN CELL; MYCOPLASMA HYORHINIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; HUMANS; MYCOPLASMA HYORHINIS; MYCOPLASMA INFECTIONS; PYRIMIDINE NUCLEOSIDES; THYMIDINE PHOSPHORYLASE;

EID: 45649084620     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.04.019     Document Type: Article

References (51)

1. de Bruin M., Temmink O.H., Hoekman K., Pinedo H.M., and Peters G.J. Role of platelet derived endothelial cell growth factor/thymidine phosphorylase in health and disease. Cancer Ther 4 (2006) 99-129
2. Beck A., Etienne M.C., Cheradame S., Fischel J.L., Formento P., Renee N., et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30A (1994) 1517-1522
3. Tanaka F., Fukuse T., Wada H., and Fukushima M. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents. Curr Pharm Biotechnol 1 (2000) 137-164
4. Longley D.B., Harkin D.P., and Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3 (2003) 330-338
5. Bollag W., and Hartmann H.R. Tumor inhibitory effects of a new fluorouracil derivative: 5′-deoxy-5-fluorouridine. Eur J Cancer 16 (1980) 427-432
6. Bajetta E., Colleoni M., Rosso R., Sobrero A., Amadori D., Comella G., et al. Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. Eur J Cancer 29A (1993) 1658-1663
7. Ishikawa T., Utoh M., Sawada N., Nishida M., Fukase Y., Sekiguchi F., et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55 (1998) 1091-1097
8. Walko C.M., and Lindley C. Capecitabine: a review. Clin Ther 27 (2005) 23-44
9. Gelmon K., Chan A., and Harbeck N. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist 11 Suppl 1 (2006) 42-51
10. Friedkin M., and Roberts D. The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue. J Biol Chem 207 (1954) 245-256
11. Liekens S., Bronckaers A., Perez-Perez M.J., and Balzarini J. Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy. Biochem Pharmacol 74 (2007) 1555-1567
12. Ishikawa F., Miyazono K., Hellman U., Drexler H., Wernstedt C., Hagiwara K., et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338 (1989) 557-562
13. Akiyama S., Furukawa T., Sumizawa T., Takebayashi Y., Nakajima Y., Shimaoka S., et al. The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. Cancer Sci 95 (2004) 851-857
14. Ninomiya Y., Miwa M., Eda H., Sahara H., Fujimoto K., Ishida M., et al. Comparative antitumor activity and intestinal toxicity of 5′-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5′-deoxy-5-fluorocytidine. Jpn J Cancer Res 81 (1990) 188-195
15. Emura T., Nakagawa F., Fujioka A., Ohshimo H., Yokogawa T., Okabe H., et al. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med 13 (2004) 249-255
16. Emura T., Suzuki N., Yamaguchi M., Ohshimo H., and Fukushima M. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol 25 (2004) 571-578
17. Hong D.S., Abbruzzese J.L., Bogaard K., Lassere Y., Fukushima M., Mita A., et al. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 107 (2006) 1383-1390
18. Temmink O.H., Emura T., de Bruin M., Fukushima M., and Peters G.J. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci 98 (2007) 779-789
19. Tham T.N., Ferris S., Kovacic R., Montagnier L., and Blanchard A. Identification of Mycoplasma pirum genes involved in the salvage pathways for nucleosides. J Bacteriol 175 (1993) 5281-5285
20. Razin S., Yogev D., and Naot Y. Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev 62 (1998) 1094-1156
21. Krause D., Yogev D., and Naot Y. Mycoplasmas which infect humans. In: McElhaney R.N., Finch L.R., and Baseman J.B. (Eds). Mycoplasmas: molecular biology and pathogenesis (1992), American Society for Microbiology, Washington, DC 417-444
22. Haflick L., and Koprowski H. Direct agar isolation of mycoplasmas from human leukaemic bone marrow. Nature 205 (1965) 713-714
23. Cimolai N. Do mycoplasmas cause human cancer?. Can J Microbiol 47 (2001) 691-697
24. Kidder M., Chan P.J., Seraj I.M., Patton W.C., and King A. Assessment of archived paraffin-embedded cervical condyloma tissues for mycoplasma-conserved DNA using sensitive PCR-ELISA. Gynecol Oncol 71 (1998) 254-257
25. Chan P.J., Seraj I.M., Kalugdan T.H., and King A. Prevalence of mycoplasma conserved DNA in malignant ovarian cancer detected using sensitive PCR-ELISA. Gynecol Oncol 63 (1996) 258-260
26. Wang R.Y., Shih J.W., Weiss S.H., Grandinetti T., Pierce P.F., Lange M., et al. Mycoplasma penetrans infection in male homosexuals with AIDS: high seroprevalence and association with Kaposi's sarcoma. Clin Infect Dis 17 (1993) 724-729
27. Huang S., Li J.Y., Wu J., Meng L., and Shou C.C. Mycoplasma infections and different human carcinomas. World J Gastroenterol 7 (2001) 266-269
28. Tsai S., Wear D.J., Shih J.W., and Lo S.C. Mycoplasmas and oncogenesis: persistent infection and multistage malignant transformation. Proc Natl Acad Sci USA 92 (1995) 10197-10201
29. Feng S.H., Tsai S., Rodriguez J., and Lo S.C. Mycoplasmal infections prevent apoptosis and induce malignant transformation of interleukin-3-dependent 32D hematopoietic cells. Mol Cell Biol 19 (1999) 7995-8002
30. Zhang S., Tsai S., Wu T.T., Li B., Shih J.W., and Lo S.C. Mycoplasma fermentans infection promotes immortalization of human peripheral blood mononuclear cells in culture. Blood 104 (2004) 4252-4259
31. Ketcham C.M., Anai S., Reutzel R., Sheng S., Schuster S.M., Brenes R.B., et al. p37 induces tumor invasiveness. Mol Cancer Ther 4 (2005) 1031-1038
32. Goodison S., Nakamura K., Iczkowski K.A., Anai S., Boehlein S.K., and Rosser C.J. Exogenous mycoplasmal p37 protein alters gene expression, growth and morphology of prostate cancer cells. Cytogenet Genome Res 118 (2007) 204-213
33. Gong M., Meng L., Jiang B., Zhang J., Yang H., Wu J., et al. p37 from Mycoplasma hyorhinis promotes cancer cell invasiveness and metastasis through activation of MMP-2 and followed by phosphorylation of EGFR. Mol Cancer Ther 7 (2008) 530-537
34. Fukushima M., Suzuki N., Emura T., Yano S., Kazuno H., Tada Y., et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides. Biochem Pharmacol 59 (2000) 1227-1236
35. Lopez L.R., van Rijswijk R.E., Wagstaff J., Pinedo H.M., and Peters G.J. The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin. Eur J Cancer 30A (1994) 1545-1549
36. Haraguchi M., Furukawa T., Sumizawa T., and Akiyama S. Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res 53 (1993) 5680-5682
37. Kong F., James G., Gordon S., Zelynski A., and Gilbert G.L. Species-specific PCR for identification of common contaminant mollicutes in cell culture. Appl Environ Microbiol 67 (2001) 3195-3200
38. Liekens S., Leali D., Neyts J., Esnouf R., Rusnati M., Dell'Era P., et al. Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds. Mol Pharmacol 56 (1999) 204-213
39. Balzarini J., Van Herrewege Y., and Vanham G. Metabolic activation of nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells. AIDS 16 (2002) 2159-2163
40. Balzarini J., De Clercq E., Mertes M.P., Shugar D., and Torrence P.F. 5-Substituted 2′-deoxyuridines: correlation between inhibition of tumor cell growth and inhibition of thymidine kinase and thymidylate synthetase. Biochem Pharmacol 31 (1982) 3673-3682
41. Neale G.A., Mitchell A., and Finch L.R. Enzymes of pyrimidine deoxyribonucleotide metabolism in Mycoplasma mycoides subsp. mycoides. J Bacteriol 156 (1983) 1001-1005
42. Merkenschlager M., Kardamakis D., Rawle F.C., Spurr N., and Beverley P.C. Rate of incorporation of radiolabelled nucleosides does not necessarily reflect the metabolic state of cells in culture: effects of latent mycoplasma contamination. Immunology 63 (1988) 125-131
43. 3H]thymidine incorporation by Mycoplasma arginini-infected cells due to enzymatic cleavage of the nucleoside. Eur J Immunol 15 (1985) 692-696
44. Desgranges C., Razaka G., Rabaud M., Bricaud H., Balzarini J., and De Clercq E. Phosphorolysis of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and other 5-substituted-2′-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets. Biochem Pharmacol 32 (1983) 3583-3590
45. de Bruin M., van Capel T., Van der B.K., Kruyt F.A., Fukushima M., Hoekman K., et al. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer 88 (2003) 957-964
46. Iltzsch M.H., el Kouni M.H., and Cha S. Kinetic studies of thymidine phosphorylase from mouse liver. Biochemistry 24 (1985) 6799-6807
47. Liekens S., Bronckaers A., Hernandez A.I., Priego E.M., Casanova E., Camarasa M.J., et al. 5′-O-Tritylated nucleoside derivatives: inhibition of thymidine phosphorylase and angiogenesis. Mol Pharmacol 70 (2006) 501-509
48. Patterson A.V., Zhang H., Moghaddam A., Bicknell R., Talbot D.C., Stratford I.J., et al. Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 72 (1995) 669-675
49. Morita T., Matsuzaki A., Suzuki K., and Tokue A. Role of thymidine phosphorylase in biomodulation of fluoropyrimidines. Curr Pharm Biotechnol 2 (2001) 257-267
50. Schwartz E.L., Baptiste N., Wadler S., and Makower D. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 270 (1995) 19073-19077
51. Drexler H.G., and Uphoff C.C. Mycoplasma contamination of cell cultures: incidence, sources, effects, detection, elimination, prevention. Cytotechnology 39 (2002) 75-90